Stay updated on Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial

Sign up to get notified when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the fostamatinib study in myelofibrosis is now displayed, with details on the study design, participants, treatments, and measured outcomes. The record indicates the study was terminated due to low accrual.
    Difference
    54%
    Check dated 2026-11-07T14:56:24.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T15:38:46.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A banner announces an NIH website terminology transition, stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.” The clinical trial record remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-24T18:22:26.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-17T20:31:57.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The footer’s site revision number changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T20:43:24.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with the standard site header and footer. The study-related content (investigators, sponsor, locations, and detailed study information) has been removed in this view.
    Difference
    19%
    Check dated 2026-09-19T22:06:16.000Z thumbnail image

Stay in the know with updates to Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.